The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Insmed's CEO keeps a newspaper story from 2014 in his office. The headline: “Insmed joins the biotech trash heap.” Now, he ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the ...

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her ...

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, ...

During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit was so toxic that it was killing patients. Only after Blueprint lowered ...

STAT's Adam Feuerstein puts all his “Biotech Doom Loop” panic-mongering aside, as he embraces luminescent moonbeams and downy-soft puppies: "Biotech is back, baby!" ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...